Background: Matrix metalloproteinase (MMP)-3, also known as stromelysis-1, is expressed in inflamed synovium of patients with rheumatoid arthritis (RA). It degrades components of articular cartilage, such as proteoglycans. In Japan MMP-3 has been used as a clinical biomarker of joint destruction and its predictive value for radiographic progression has been reported. Objectives: W aimed to confirm a relation between baseline MMP-3 and radiographic progression at 1 year and to examine the association of the MMP-3 level with ultrasonography (US) findings. Methods: A total of 259 (213 women) consecutive patients with RA were enrolled. We collected baseline data, that included the patient's age, sex, disease duration, use of glucocorticoid or disease modifying antirheumatic drugs, Disease Activity Score-28, and modified total Sharp score (mTSS); MMP-3 and, C reactive protein levels;, rheumatoid factor or anti-citrullinated peptide antibody status,; and the power doppler score (PD) of US assessment of digits and wrists. Baseline MMP-3 level was analyzed in association with the baseline PD value and changes ( ) in mTSS, erosion score ( ERN), joint space narrowing ( JSN) at 1 year from baseline by Pearson's correlation method. Correlations between MMP-3 and mTSS, or PD were also analyzed. Multiple regression analysis was performed, with mTSS as the outcome for baseline variables. Statistical analysis was performed separately by sex because the upper normal limits of MMP-3 differ between the sexes (men ≤121ng/ml, women ≤59.7 ng/ml). Results: There was a weak correlation between the baseline MMP-3 level and baseline PD score in men. There was also moderate correlations between baseline MMP-3 level and structural damage at 1 year only in men. There was no predictive value for baseline MMP-3 level in women in terms of structural damage at 1 year. Multiple regression analysis revealed that the baseline MMP-3 level correlated independently with the mTSS only in men (p=0.0031), whereas in the women the baseline PD score was correlated independently with the mTSS (p=0.0003). Conclusions: The baseline MMP-3 level was a good predictor of deterioration of the mTSS at 1 year in male patients with RA, but not in female patients. On the other hand, the baseline PD score was a useful predictor of joint destruction in female patients with RA. Background: Anti-cyclic citrullinated peptide antibodies (Anti-CCP Ab) are wellestablished serological markers that show high sensitivity and specificity in diagnosing early rheumatoid arthritis (RA). Furthermore, Anti-CCP Ab is reported to be associated with bone erosions of RA. Therefore, Anti-CCP Ab positive RA patient can be a candidate for intensive treatment. Objectives: Upper measurement limit of Anti-CCP Ab increased recently up to 1200 units. High level of Anti-CCP Ab may be a predictor of the profound therapy for RA. To understand the importance of Anti-CCP Ab level, we evaluated RA patients with high titer Anti-CCP Ab in relationship to the other activity markers of RA and the intensity of the treatment for RA. Methods: Total of 186 RA patients with Anti-CCP Ab higher than 30 units was included in this study. Baseline markers such as CRP, MMP-3, RF and anti-CCP Ab were measured at the entry of the study. Relationship among these markers ware evaluated and examined using statistical significance for the single-factor ANOVA and the multiple comparisons. Among those cases 131 cases were treated conservatively with biologics and/or DMARDs and were followed up more than one year. We graded them from I to IV by the intensity of the treatment. Grade I: Biological agent. Grade II: Methotrexate (MTX) more than 12mg or combination with more than 3 DMARDS Grade III: MTX 6-11mg or combination
